Garg Pushkal

EVP Chief R&DALNYLAM PHARMACEUTICALS, INC. (ALNY) · full profile →Form 4 · filed Mar 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.1M
Net Open-Market Flow
-$1.1M
Transactions
16
15 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 3, 2026Sell(S)640$320.48$205K24K
Mar 3, 2026Sell(S)463$321.50$149K23K
Mar 3, 2026Sell(S)355$316.74$112K25K
Mar 3, 2026Sell(S)317$319.06$101K25K
Mar 2, 2026Sell(S)107$328.71$35K26K
Mar 2, 2026Sell(S)182$329.71$60K25K
Mar 2, 2026Sell(S)87$330.85$29K25K
Mar 2, 2026Sell(S)101$331.93$34K25K
Mar 2, 2026Sell(S)42$332.64$14K25K
Mar 2, 2026Sell(S)50$323.62$16K27K
Mar 2, 2026Sell(S)277$325.63$90K26K
Mar 2, 2026Sell(S)97$324.65$31K27K
Mar 2, 2026Grant(A)5K$027K
Mar 2, 2026Sell(S)421$326.81$138K26K
Mar 2, 2026Sell(S)353$327.67$116K26K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 2, 2026Grant(A)10K$010K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001735276-26-000052) within minutes of acceptance. Every field above traces to the original document. Verify it directly: